Mon, 18 Nov, 2024 - 11:06
Investors, relieved to have a clear-cut US election winner and fired up about the prospect of tax cuts and deregulation under a Donald Trump administration, have sent many US share prices zooming higher but not the pharmaceutical companies.
The expectation that Mr Trump will impose a 10% to 20% tariff across all imports is not a concern for US pharma companies — who have extensive manufacturing bases in Ireland — or the indigenous industry here.
CONNECT WITH US TODAY
Be the first to know the latest news and updates




